APA (7th ed.) Citation

Lund, L. H., Lam, C. S., Pizzato, P. E., Gabrielsen, A., Michaëlsson, E., Nelander, K., . . . Shah, S. J. (2023). Rationale and design of ENDEAVOR: A sequential phase 2b–3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction. European Journal of Heart Failure, 25(9), 1696. https://doi.org/10.1002/ejhf.2977

Chicago Style (17th ed.) Citation

Lund, Lars H., et al. "Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction." European Journal of Heart Failure 25, no. 9 (2023): 1696. https://doi.org/10.1002/ejhf.2977.

MLA (9th ed.) Citation

Lund, Lars H., et al. "Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction." European Journal of Heart Failure, vol. 25, no. 9, 2023, p. 1696, https://doi.org/10.1002/ejhf.2977.